News

News

Rapid relief of pain in oral mucositis, New episil® oral liquid approved in China (PDF 197 KB)
Business Overview of Pipeline Products (Consolidated Financial Results for the Fiscal Year Ended December 31, 2018) (PDF 360 KB)
Consolidated Financial Results for the Fiscal Year Ended December 31, 2018 (under IFRS) (PDF 257 KB)
Notice of Review Progress of episil® oral liquid in China (PDF 157 KB)
Solasia Initiates Phase III program for SP-04(PledOx®) in Japan (PDF 105 KB)
Research report about Solasia was updated by Shared Research Inc.
Notice of Guangzhou Office Opening
SP-01 Sancuso® First Delivery (PDF 72 KB)
Business Overview of Pipeline Products (Third Quarter of the Fiscal Year Ending December 31, 2018) (PDF 152 KB)
Consolidated Financial Results for the Nine Months of the Fiscal Year Ending December 31, 2018 (under IFRS) (PDF 227 KB)
Research report about Solasia was updated by Shared Research Inc.
IR Report (Bridge Report) about Solasia
Announcement Regarding the Pricing for the Issuance of New Shares and Secondary Offering of Shares (PDF 54 KB)
Announcement Regarding Issuance of New Shares and Secondary Offering of Shares (PDF 102 KB)
Announcement Concerning Signing of License and Distribution Agreement for SP-02 (darinaparsin injection) in Latin America (PDF 168 KB)
Solasia acquires exclusive license to develop and commercialize episil® (oral liquid) in South Korea (PDF 167 KB)
Consolidated Financial Results for the Six Months of the Fiscal Year Ending December 31, 2018 (under IFRS) (PDF 182 KB)
Sancuso®, the First Transdermal Patch for the Prevention of CINV Approved in China (PDF 253 KB)
Announcement Concerning Signing of Commitment Line Agreement (PDF 198 KB)
Notice of Review Progress of Sancuso® in China (PDF 178 KB)
Research report about Solasia was updated by Shared Research Inc.
Announcement Concerning the Development Plan of PledOx® (PDF 87 KB)
Announcement Concerning Signing of Commitment Line Agreement (PDF 204 KB)
episil® (oral liquid) Launched in Japan (PDF 185 KB)
Consolidated Financial Results for the First Three Months of the Fiscal Year Ending December 31, 2018 (under IFRS) (PDF 225 KB)
IR Report (Bridge Report) about Solasia
Notice of the Resolutions Adopted at the 10th Annual General Meeting of Shareholders (PDF 49 KB)
Research report about Solasia was updated by Shared Research Inc.
Notice of the 10th Annual General Meeting of Shareholders (PDF 317 KB)
Consolidated Financial Results for the Fiscal Year Ended December 31, 2017 (under IFRS) (PDF 204 KB)
Announcement Regarding Change of Directors and Auditors (PDF 154 KB)
Closing of Phase I Clinical Study of SP-04(PledOx) (PDF 83 KB)
Summary of Financial Results 2017 (PDF 25 KB)
Research report about Solasia was updated by Shared Research Inc.
Notice Regarding Status of SP-01 and Revision to Financial Forecasts (PDF 143 KB)
Consolidated Financial Results for the Nine Months of the Fiscal Year Ending December 31, 2017 (under IFRS) (PDF 236 KB)
PledPharma and Solasia enter license agreement to develop and commercialize PledOx® in Asia (PDF 87 KB)
Research report about Solasia is issued by Shared Research Inc.
Consolidated Financial Results for the Six Months of the Fiscal Year Ending December 31, 2017 (under IFRS) (PDF 232 KB)
Solasia Announces Approval of episil® (oral liquid) in Japan (PDF 156 KB)
IR Report (Bridge Report) about Solasia (PDF 1 MB)
Solasia listed it’s shares to Tokyo Exchange Mothers.

Information for use of our products

The site you are about to access is intended to provide information for medical professionals in Japan. It is designed to allow users to better understand Solasia's products.

I have read and understood above

Page Top

SELECT YOUR LANGUAGE